Results 41 to 50 of about 53,892 (275)

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Mantle Cell Lymphoma Presenting with Acute Bilateral Ophthalmoplegia

Türk Oftalmoloji Dergisi, 2017
A 72-year-old woman presented with acute onset of double vision, bilateral complete blepharoptosis, and nearly complete ophthalmoplegia. Orbital and brain magnetic resonance imaging were normal.
Yaran Koban, Hatice Özlece, Orhan Ayar, Mustafa Koç, Hüseyin Çelik, Zeliha Yazar, Ayşe Burcu   +6 more
doaj   +1 more source

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]

, 2011
Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V, Fanale MA, Hasenclever D, Katrina Farrell, Mike Leach, Orlandi E, Pamela Mckay, Savage KJ, Stein H   +8 more
core   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

Suboccipital lateral injection of intrathecal chemotherapy in a patient with mantle cell lymphoma [PDF]

, 2004
Background: Even today patients who suffer from mantle cell lymphoma have a poor prognosis, especially when the CNS is involved. To confirm the diagnosis of meningeosis lymphomatosa, asservation of the liquor cerebrospinalis is necessary.
Bruning, R., Dühmke, Eckhart, Pachmann, S., Schaffer, Moshe   +3 more
core   +1 more source

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases [PDF]

, 2017
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors.
Berno, Tamara, Bertorelle, Roberta, Facco, Monica, Frezzato, Federica, Imbergamo, Silvia, Piazza, Francesco, Piva, Elisa, Pizzi, Marco, Riva, Marcello, Scomazzon, Edoardo, Semenzato, Gianpietro, Trentin, Livio, Visentin, Andrea   +12 more
core   +1 more source

Targeting WTAP/ROR1/WNT5A‐Mediated Crosstalk Between Glioma Stem Cells and Macrophages to Normalize Tumor Vasculature and Enhance Chemotherapy

Advanced Science, EarlyView.
In hypoxic microenvironment, WNT5A is predominantly secreted by tumor‐associated macrophages. Hypoxia‐induced WTAP mediates ROR1 stability by m6A modifications in a HuR‐dependent manner in Glioma stem cells (GSCs). WNT5A activates the WNT pathway via ROR1 binding on GSCs, driving glioma‐derived endothelial cells (GDECs) differentiation.
Xiaoyong Chen, Bo Pang, Yun Liu, Jiangwei Wang, Lanhui Zheng, Yuzhou Chang, Yingxuan Sun, Haoyuan Sun, Huiyuan Chen, Jiawei Cai, Zanyi Wu, Qing Chang, Yongzhi Wang, Dezhi Kang, Tao Jiang, Ruichao Chai   +15 more
wiley   +1 more source

Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis

Haematologica, 2011
Background Cases of mantle cell lymphoma with indolent behavior have been reported, but are poorly identified by current clinical risk models. Early studies found peripheral blood involvement to be an adverse prognostic factor; however, cases of a ...
Sarah L. Ondrejka, Raymond Lai, Stephen D. Smith, Eric D. Hsi   +3 more
doaj   +1 more source

Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trial. [PDF]

Hemasphere
HemaSphere, Volume 10, Issue 1, January 2026.
Ragaini S, Genuardi E, Alessandria B, Civita AM, Evangelista A, Drandi D, Montana C, Russo S, Consoli C, Pironti M, Hohaus S, Musuraca G, Cascavilla N, Ghiggi C, Tani M, Gaidano G, Olivieri J, Usai SV, Di Renzo N, Luppi M, Stefoni V, Cavallo F, Ladetto M, Ferrero S.   +23 more
europepmc   +2 more sources

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source